Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Oct. 14 — The U.S. will allow individuals subject to U.S. jurisdictions to engage in joint medical research projects with Cuban nationals, the White House announced Oct. 14.
The White House also announced that the Treasury Department's Office of Foreign Assets Control (OFAC) will permit approval of Cuban-created pharmaceuticals by the Food and Drug Administration and will allow them to be imported for marketing, sale and distribution.
An OFAC final rule implementing the changes is set to be published in an Oct. 17 Federal Register notice.
The announcement expands the thawing of Cuban-U.S. relations. As a result of the 54-year-old U.S. blockade of the country, Cuba developed its own biopharmaceutical industry, including drugs and vaccines that have attracted the interest of U.S. biopharmas and prompted U.S. citizens to participate in medical tourism in Cuba (10 LSLR 18, 9/16/16).
The details of the changes the White House announced for health-related transactions include:
These are among a number of changes that will be included in Treasury and Commerce department regulations.
The U.S. Treasury Department says on its website: “These changes are intended to expand opportunities for scientific collaboration by authorizing certain transactions related to Cuban-origin pharmaceuticals and joint medical research; improve living conditions for Cubans by expanding existing authorizations for grants and humanitarian-related services; increase people-to-people contact in Cuba by facilitating authorized travel and commerce; facilitate safe travel between the United States and Cuba by authorizing civil aviation safety-related services; and bolster trade and commercial opportunities by expanding and streamlining authorizations relating to trade and commerce.”
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
The pre-publication version of the Federal Register notice is at http://src.bna.com/jo1.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)